News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Seeking Alpha Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its …
Stifel Nicolaus has reduced its price target for Nkarta (NASDAQ:NKTX) from $11 to $10, while maintaining a "buy" rating, indicating a potential upside of 334.78% from the previous close. The company's shares opened at $2.30 and were down 3.8% after reporting a quarterly loss …
Spartacus Acquisition Corp. II reported a net income of $1.93 million for Q2 2026, with diluted EPS of $0.06. This income is primarily from interest generated by its $230 million trust account, as the blank-check company is actively seeking a business combination within the …
Spartacus Acquisition Corp. II (TMTS), a Cayman Islands SPAC, reported net income of $1,928,284 for Q2 2026 and $2,828,130 for the first half of 2026, primarily driven by interest earned on trust investments. The company's Trust Account held $232,797,250 as of June 30, 2026, …
Nkarta, Inc. (NKTX) has seen its average 12-month price target cut to $11 from $11.33 by analysts, with forecasts ranging from $9 to $14 per share. This updated target suggests a potential upside of approximately 347% based on the recent closing price. The consensus …
H.C. Wainwright lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $14 from $16, while maintaining a Buy rating. The firm's decision followed Nkarta's Q2 2026 earnings report and an update on its Ntrust-1 and Ntrust-2 trials for NKX019 in autoimmune diseases, with initial …
(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower other income. The company has also provided a clinical update on …
Nkarta, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, states that unlimited access to the full content requires a TradingView subscription.
Nkarta (NASDAQ:NKTX) reported a quarterly loss of $0.54 per share, missing the consensus estimate by $0.18. Despite the earnings miss, NKTX shares rose 2.1% to $2.46 in midday trading. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price …
Nkarta, a biotechnology company, reported a Q2 2026 net loss of $40.4 million, or $(0.54) per share, significantly missing analyst estimates and widening from the previous year. This increase is attributed to higher operating expenses, particularly in general and administrative costs. Despite the loss, …
Nkarta, Inc. reported its second quarter 2026 financial results, highlighting continued enrollment in its Ntrust-1 and Ntrust-2 clinical trials for autoimmune diseases at the 4 billion cell dose level, with initial data expected in 2026. The company also announced that its cash balance of …
Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $10.75, significantly above its current share price of $2.41. The company reported a quarterly loss of $0.37 per share, beating analyst estimates. Institutional investors …
Nkarta Inc (NKTX) has an earnings forecast score of 8.67, ranking 75th in its industry. Analysts have set an average price target of $11.00, with a high of $16.00 and a low of $8.00, predominantly recommending a "Buy" for the stock. The company's EPS …
Nkarta (NKTX) is scheduled to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.39 per share. The company previously exceeded estimates in Q1 by reporting a loss of $0.37 per share. NKTX shares are …
This article provides a detailed stock analysis of Nkarta Inc (NKTX), highlighting its weak fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price of …
This article provides a technical analysis of Nkarta Inc (NKTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that NKTX is suitable for range-bound swing trading, with most indicators signaling "Sell" or "Oversold," and …
This article provides a brief overview of Nkarta, Inc. (NASDAQ: NKTX), focusing on its financial data and revenue breakdown. It points to the company's financials page on TradingView, indicating where users can find statements, statistics, dividends, earnings, and segment information. The content itself seems …
Search by ticker symbol or company name and select a result to open its chart.